Halozyme Deal Could Yield $83M, Wireless Health Leaders Converge, Readers Vote on Worst Drug Names, & More San Diego Life Sciences News

Xconomy San Diego — 

Much of the action this week was taking place downtown, at the 6th annual Convergence Summit hosted by the nonprofit Wireless-Life Sciences Alliance. The three-day conference included CEOs, entrepreneurs, investors, executives, and innovators—and we’ve got the highlights of that and other area life sciences news wrapped up here.

—San Diego’s Qualcomm (NASDAQ: QCOM), the largest wireless chipmaker in the world, said during the summit that it’s helping the X Prize Foundation set the ground rules for a proposed $10 million Tricorder X Prize. X Prize organizers want a real-life medical tricorder—like the one Dr. McCoy used on Star Trek—that is portable, uses wireless sensors, and has the capability to rapidly diagnose patients better than or equal to a panel of board-certified physicians.

Eric Topol, the Scripps Health cardiologist and director of the Scripps Translational Science Institute, said during his talk at the convergence summit that he wants to start a new medical school for tech-minded students in San Diego. Topol says medical students should be learning how to handle new wireless technologies and genomics in their practice. Topol was instrumental in founding the Cleveland Clinic Lerner College of Medicine in 2002.

—Exton, PA-based ViroPharma (NASDAQ: VPHM) agreed to pay San Diego’s Halozyme Therapeutics (NASDAQ: HALO) as much as $83 million to license Halozyme’s recombinant human hyaluronidase. ViroPharma wants to develop the Halozyme compound as an experimental injection medication for a rare genetic disorder that causes potentially life-threatening swelling.

—San Diego’s Meritage Pharma said its experimental drug for a little-known condition called eosinophilic esophagitis (EoE) passed a mid-stage clinical trial of 71 children. The study found … Next Page »

Single PageCurrently on Page: 1 2